Pharma tycoon is benefiting from robust sales in the US, a market that contributes 30 percent to his generics maker Cadila Healthcare's $1.1 billion annual revenues. USFDA approval to sell an anti-viral drug led to an uptick in shares in August. The Ahmedabad-headquartered pharma firm was one of seven Indian firms to get a licence from US-based Gilead Sciences to make a low cost, generic version of its Hepatitis C drug Sovaldi. Cadila also has a string of manufacturing and distribution alliances with firms such as Bayer, Takeda and Hospira.